Cardiovascular Diabetology

Cardiovascular Diabetology is a fully open access journal published by BioMed Central, part of Springer Nature. Founded in 2002 as the first journal dedicated exclusively to the link between diabetes and cardiovascular disorders, it carries electronic ISSN 1475-2840 and reports a 2025 impact factor of 15.6.Cardiovascular Diabetology 是施普林格·自然旗下 BioMed Central 出版的全开放获取期刊，2002 年创刊，为糖尿病与心血管疾病交叉领域首个专门刊物，电子版编号 1475-2840，2025 年影响因子为 15.6。^[1]

Scope

• Scope: the journal considers manuscripts on all aspects of the diabetes and cardiovascular interrelationship and the metabolic syndrome, including clinical, genetic, experimental, pharmacological, epidemiological and molecular biology research, and was the first in the field to cover this link exclusively.学科定位： 收稿范围涵盖糖尿病与心血管疾病相互关系及代谢综合征的所有方面，包括临床、遗传、实验、药理、流行病学与分子生物学研究，是该领域首个只关注这一交叉方向的期刊。^[2]
• Topics: the pathophysiological links between diabetes and cardiovascular disease, the cardiovascular-kidney-metabolic syndrome, atherosclerosis and altered glucose metabolism, diabetic cardiomyopathy, cardiovascular effects of GLP-1 and SGLT2 therapies, and proteomic and metabolomic biomarkers.收录主题： 糖尿病与心血管疾病的病理生理关联，心血管-肾-代谢综合征，动脉粥样硬化与血糖代谢改变，糖尿病心肌病，GLP-1 与 SGLT2 等药物对心血管结局的影响，以及蛋白质组学与代谢组学生物标志物。
• Article types: research articles, reviews, case reports, comments, hypothesis papers, methodology articles, study protocols and matters arising.文章体裁： 原创研究、综述、病例报告、评论、假说论文、方法学论文、研究方案与学术商榷文章。
• Publishing model: fully open access under Creative Commons licences, with article processing charge reductions for corresponding authors in the least developed countries.出版模式： 完全开放获取，采用知识共享许可，对最不发达国家的通讯作者有版面费减免。
• Indexing and metrics: covered by the SCIE, Scopus, Medline, PubMed Central, DOAJ and EMBASE, with a 2025 impact factor of 15.6 and a five-year impact factor of 13.6.收录与指标： 被 SCIE、Scopus、Medline、PubMed Central、DOAJ 与 EMBASE 收录，2025 年影响因子 15.6、五年影响因子 13.6。

History

• Founded: the journal was founded in 2002, an early dedicated venue as research on cardiovascular complications of diabetes grew from a peripheral topic into a discipline of its own.创刊： 2002 年创刊，是糖尿病心血管并发症研究从边缘课题成长为独立学科过程中的早期专门出版物。
• Founding editor: founding editor Enrique Fisman has led the journal throughout, and the official site still lists him as founding editor and editor-in-chief.创刊主编： 创刊主编 Enrique Fisman 长期主持刊物，刊物官网至今仍将其列为创刊编辑兼主编。^[3]
• Expansion: in 2025 the publisher launched the companion title Cardiovascular Diabetology - Endocrinology Reports, forming a journal family around the diabetes and cardiology interface.刊物扩张： 2025 年出版方推出姊妹刊 Cardiovascular Diabetology - Endocrinology Reports，形成糖尿病心血管交叉方向的刊物群。
• Title history: no renaming on record, the title Cardiovascular Diabetology has been in use since 2002.更名史： 无更名记录，创刊至今沿用 Cardiovascular Diabetology 刊名。

Editors

• Editor-in-chief: Enrique Fisman, MD, of the Sackler Faculty of Medicine at Tel Aviv University in Israel, working on echocardiography, exercise cardiology and epidemiology.现任主编： Enrique Fisman，医学博士，以色列特拉维夫大学萨克勒医学院，研究方向含超声心动图、运动心脏病学与流行病学。^[3]
• Deputy editor: Francisco Westermeier, PhD, of FH JOANNEUM University of Applied Sciences in Graz, Austria.副主编： Francisco Westermeier，哲学博士，奥地利格拉茨 FH JOANNEUM 应用科学大学。
• Editorial board: 64 associate editors and 31 editorial board members, some 103 independent scholars in total covering 29 countries and regions, with roughly 18 from mainland China, 13 from the United States, 12 from Italy, 8 from Israel and 7 from Japan.编委构成： 副编辑 64 名、编辑委员会成员 31 名，全编团约 103 位独立学者、覆盖 29 个国家与地区，其中中国大陆背景学者约 18 人，美国 13 人、意大利 12 人、以色列 8 人、日本 7 人。
• Submission and review: submissions go through the Springer Nature submission system under single anonymized peer review, with accepted articles published online immediately.投稿与评审： 经施普林格·自然投稿系统投稿，实行单盲同行评审，录用后即时在线发表。
• Community engagement: four social media editors, including scholars from Shanghai Jiao Tong University and the IRCCS Galeazzi institute in Italy, handle research dissemination.学术社群： 另设社交媒体编辑 4 名，包括上海交通大学与意大利 IRCCS Galeazzi 研究所的学者，负责成果传播。